Пре- и посттрансплантационные факторы, ассоциированные с первичной недостаточностью тяжелой дисфункцией трансплантата после аллогенной трансплантации гемопоэтических стволовых клеток при хроническом миелоидном лейкозеPre- and post-transplantation factors associated with primary graft failure severe poor function after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia

The online version of this article has a Supplementary Appendix. Background Protein phosphatase 2A is a novel potential therapeutic target in several types of chronic and acute leukemia, and its inhibition is a common event in acute myeloid leukemia. Upregulation of SET is essential to inhibit protein phosphatase 2A in chronic myeloid leukemia, but its importance in acute myeloid leukemia has n...

Background: Chronic myeloid leukemia (CML) is a myeloproliferative hematopoietic malignancy with a heterogeneous proliferation of hematopoietic cells in the bone marrow. The ocular manifestations are rare symptoms of CML. In this case report, a CML patient with retinal hemorrhage is reported as an uncommon symptom. Case presentation: A 35-year-old man was referred due to decreased right eye vi...

In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesuccinate (formerly called homoharringtonine) is a natural alkaloid that inhibits protein synthesis and induces cell death. Om...

Background: Leptin has been implicated in the differentiation and proliferation of hematopoietic cells. Leukemia inhibitory factor (LIF) may play an important role, along with Interleukin-6 (IL-6) and granulocyte colony stimulating factor (G- CSF), in the regulation of early hematopoietic stem cells. The aim of the study was to evaluate serum level of leptin, LIF, and IL-6 in myeloid leukemia p...

BACKGROUND Tyrosine kinase inhibitors, such as imatinib, are not considered curative for chronic myeloid leukemia--regardless of the significant reduction of disease burden during treatment--since they do not affect the leukemic stem cells. However, the stochastic nature of hematopoiesis and recent clinical observations suggest that this view must be revisited. DESIGN AND METHODS We studied t...

Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid le...

Blast crisis, closely resembling acute leukemia, is the usual terminal event in chronic myeloid leukemia. Using physical ("fingerprint") and cultural (colony-forming) methods, we have demonstrated distinctive patterns in the stable phase of chronic myeloid leukemia and in blast crisis. An unusual fingerprint alteration preceding the onset of the terminal phase is noted, and cell culture perturb...

It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib. To characterize the clinical outcomes and profiles of chronic phase chronic myeloid leukemia patients who could discontinue imatinib, we conducted a nationwide survey in Japan. Among 3,242 imatinib-treated chronic myeloid leukem...

Background Among all malignances, leukemia has the greatest effects on patients 'psychological aspects. Anxiety is common problem in leukemia patients (especially in children). Since no study has addressed the effect of Slow-stroke back massage (SSBM) on anxiety in the pediatrics with chronic leukemia, this investigation aimed to controlling anxiety through a non-drug method (such as SSBM) in c...